thalidomide has been researched along with Leukemia in 28 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the efficacy of thalidomide for treating acute leukemia (AL)." | 9.10 | [The short-term outcomes of patients with acute leukemia treated by thalidomide]. ( Li, YG; Liu, YF; Mu, HR; Sui, HT; Wang, ML; Wu, HG, 2003) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 9.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| "Thalidomide was found to have immunosuppressive properties and it has been used in a limited number of children with cGVHD." | 6.69 | The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. ( Arrigo, C; Balduzzi, A; Locasciulli, A; Miniero, R; Nesi, F; Nicolini, B; Rovelli, A; Uderzo, C; Vassallo, E, 1998) |
| "Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, which has pleotropic activity, including antiangiogenic and antineoplastic properties." | 6.44 | The evolving role of lenalidomide in the treatment of hematologic malignancies. ( Dimopoulos, MA; Kastritis, E, 2007) |
| "Thalidomide treatment significantly decreased the invasive cells number through Matrigel and human umbilical vein endothelial cells when compared with the controls." | 5.35 | Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1. ( Li, J; Liu, P; Lu, H; Xu, B, 2009) |
| "To study the efficacy of thalidomide for treating acute leukemia (AL)." | 5.10 | [The short-term outcomes of patients with acute leukemia treated by thalidomide]. ( Li, YG; Liu, YF; Mu, HR; Sui, HT; Wang, ML; Wu, HG, 2003) |
| "Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD)." | 5.08 | Thalidomide as salvage therapy for chronic graft-versus-host disease. ( Blume, KG; Chao, N; Forman, SJ; Kashyap, A; Long, GD; Margolin, K; Molina, A; Nademanee, A; Negrin, RS; Niland, JC; O'Donnell, MR; Parker, PM; Planas, I; Schmidt, GM; Smith, EP; Snyder, DS; Somlo, G; Spielberger, R; Stein, AS; Stepan, DE; Wilsman, K; Zwingenberger, K, 1995) |
| " Thalidomide, lenalidomide and bortezomib have all been shown to be highly effective in multiple myeloma, and JAK2-inhibitors have entered phase II studies of patients with JAK2-positive primary myelofibrosis and related diseases." | 4.84 | [Novel medical treatment modalities in hematology]. ( Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A, 2008) |
| " When all conventional therapy has failed, an angiogenesis inhibitor may be successfully used alone, as has been demonstrated in the treatment of multiple myeloma by thalidomide." | 4.81 | Angiogenesis-dependent diseases. ( Folkman, J, 2001) |
| "We evaluated re-induction incorporating carfilzomib-thalidomide-dexamethasone (KTd) and autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma (NDMM) refractory, or demonstrating a suboptimal response, to non-IMID bortezomib-based induction." | 4.31 | Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial. ( Horvath, N; Kalff, A; Kerridge, I; Khong, T; Lee, E; Morris, E; Quach, H; Reynolds, J; Spencer, A; Turner, R, 2023) |
| " Total therapy trials (TT; TT2(-/+) thalidomide) and TT3 (TT3a with bortezomib, thalidomide; TT3b with additional lenalidomide) offered the opportunity to examine the contribution of these immune-modulatory agents to MDS-associated cytogenetic abnormalities (MDS-CA) and clinical MDS or acute leukemia ("clinical MDS/AL")." | 3.79 | Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. ( Abdallah, AO; Bailey, C; Barlogie, B; Chauhan, N; Cottler-Fox, M; Crowley, J; Epstein, J; Heuck, CJ; Hoering, A; Johann, D; Muzaffar, J; Petty, N; Rosenthal, A; Sawyer, J; Sexton, R; Singh, Z; Usmani, SZ; van Rhee, F; Waheed, S; Yaccoby, S, 2013) |
| "Thalidomide and its analogs are effective agents in the treatment of multiple myeloma." | 3.76 | Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. ( Bladé, J; Cibeira, MT; Cid, MC; Corbera-Bellalta, M; Esparza, J; Izco, N; Lozano, E; Segarra, M; Vilardell, C, 2010) |
| "5-Hydroxy- and 4-amino-2-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33 and 4APP-33, respectively) have been shown to possess cell differentiation-inducing activity toward human leukemia cell line HL-60." | 3.73 | Cell differentiation inducers derived from thalidomide. ( Hashimoto, Y; Katayama, R; Miyachi, H; Naito, M; Noguchi, T, 2005) |
| "Thalidomide was found to have immunosuppressive properties and it has been used in a limited number of children with cGVHD." | 2.69 | The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. ( Arrigo, C; Balduzzi, A; Locasciulli, A; Miniero, R; Nesi, F; Nicolini, B; Rovelli, A; Uderzo, C; Vassallo, E, 1998) |
| "Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, which has pleotropic activity, including antiangiogenic and antineoplastic properties." | 2.44 | The evolving role of lenalidomide in the treatment of hematologic malignancies. ( Dimopoulos, MA; Kastritis, E, 2007) |
| "Thalidomide treatment significantly decreased the invasive cells number through Matrigel and human umbilical vein endothelial cells when compared with the controls." | 1.35 | Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1. ( Li, J; Liu, P; Lu, H; Xu, B, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (21.43) | 18.7374 |
| 1990's | 3 (10.71) | 18.2507 |
| 2000's | 12 (42.86) | 29.6817 |
| 2010's | 6 (21.43) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Noguchi, T | 1 |
| Miyachi, H | 1 |
| Katayama, R | 1 |
| Naito, M | 1 |
| Hashimoto, Y | 1 |
| Fernández Braña, M | 1 |
| Acero, N | 1 |
| Añorbe, L | 1 |
| Muñoz Mingarro, D | 1 |
| Llinares, F | 1 |
| Domínguez, G | 1 |
| Turner, R | 1 |
| Quach, H | 1 |
| Horvath, N | 1 |
| Kerridge, I | 1 |
| Lee, E | 1 |
| Morris, E | 1 |
| Kalff, A | 1 |
| Khong, T | 1 |
| Reynolds, J | 1 |
| Spencer, A | 1 |
| Usmani, SZ | 1 |
| Sawyer, J | 1 |
| Rosenthal, A | 1 |
| Cottler-Fox, M | 1 |
| Epstein, J | 1 |
| Yaccoby, S | 1 |
| Sexton, R | 1 |
| Hoering, A | 1 |
| Singh, Z | 1 |
| Heuck, CJ | 1 |
| Waheed, S | 1 |
| Chauhan, N | 1 |
| Johann, D | 1 |
| Abdallah, AO | 1 |
| Muzaffar, J | 1 |
| Petty, N | 1 |
| Bailey, C | 1 |
| Crowley, J | 1 |
| van Rhee, F | 1 |
| Barlogie, B | 1 |
| Moskowitz, AJ | 1 |
| Saenz, DT | 1 |
| Fiskus, W | 1 |
| Qian, Y | 1 |
| Manshouri, T | 1 |
| Rajapakshe, K | 1 |
| Raina, K | 1 |
| Coleman, KG | 1 |
| Crew, AP | 1 |
| Shen, A | 1 |
| Mill, CP | 1 |
| Sun, B | 1 |
| Qiu, P | 1 |
| Kadia, TM | 1 |
| Pemmaraju, N | 1 |
| DiNardo, C | 1 |
| Kim, MS | 1 |
| Nowak, AJ | 1 |
| Coarfa, C | 1 |
| Crews, CM | 1 |
| Verstovsek, S | 1 |
| Bhalla, KN | 1 |
| Ge, Y | 2 |
| Byun, JS | 1 |
| De Luca, P | 1 |
| Gueron, G | 1 |
| Yabe, IM | 1 |
| Sadiq-Ali, SG | 1 |
| Figg, WD | 2 |
| Quintero, J | 1 |
| Haggerty, CM | 2 |
| Li, QQ | 1 |
| De Siervi, A | 1 |
| Gardner, K | 2 |
| Hasselbalch, HC | 1 |
| Birgens, H | 1 |
| Dufva, IH | 1 |
| Dalseg, AM | 1 |
| Brown, Pde N | 1 |
| Jensen, MK | 1 |
| Vangsted, A | 1 |
| Noman, AS | 1 |
| Koide, N | 1 |
| Khuda, II | 1 |
| Dagvadorj, J | 1 |
| Tumurkhuu, G | 1 |
| Naiki, Y | 1 |
| Komatsu, T | 1 |
| Yoshida, T | 1 |
| Yokochi, T | 1 |
| Liu, P | 1 |
| Li, J | 1 |
| Lu, H | 1 |
| Xu, B | 1 |
| Segarra, M | 1 |
| Lozano, E | 1 |
| Corbera-Bellalta, M | 1 |
| Vilardell, C | 1 |
| Cibeira, MT | 1 |
| Esparza, J | 1 |
| Izco, N | 1 |
| Bladé, J | 1 |
| Cid, MC | 1 |
| Okawa, Y | 1 |
| Aiba, K | 1 |
| Park, B | 1 |
| Sung, B | 1 |
| Yadav, VR | 1 |
| Chaturvedi, MM | 1 |
| Aggarwal, BB | 1 |
| Wellbrock, J | 1 |
| Fiedler, W | 1 |
| Wang, ML | 1 |
| Mu, HR | 1 |
| Liu, YF | 1 |
| Li, YG | 1 |
| Wu, HG | 1 |
| Sui, HT | 1 |
| HUTCHISON, JH | 1 |
| BACH, A | 2 |
| BICHEL, J | 2 |
| HEJGAARD, JJ | 2 |
| SUGIURA, K | 1 |
| WUEST, HM | 1 |
| Montano, I | 1 |
| Rustici, G | 1 |
| Freebern, WJ | 1 |
| Cui, W | 1 |
| Ponciano-Jackson, D | 1 |
| Chandramouli, GV | 1 |
| Gardner, ER | 1 |
| Abu-Asab, M | 1 |
| Tsokos, M | 1 |
| Jackson, SH | 1 |
| Kastritis, E | 1 |
| Dimopoulos, MA | 1 |
| Parker, PM | 1 |
| Chao, N | 1 |
| Nademanee, A | 1 |
| O'Donnell, MR | 1 |
| Schmidt, GM | 1 |
| Snyder, DS | 1 |
| Stein, AS | 1 |
| Smith, EP | 1 |
| Molina, A | 1 |
| Stepan, DE | 1 |
| Kashyap, A | 1 |
| Planas, I | 1 |
| Spielberger, R | 1 |
| Somlo, G | 1 |
| Margolin, K | 1 |
| Zwingenberger, K | 1 |
| Wilsman, K | 1 |
| Negrin, RS | 1 |
| Long, GD | 1 |
| Niland, JC | 1 |
| Blume, KG | 1 |
| Forman, SJ | 1 |
| Fernandez, LP | 1 |
| Schlegel, PG | 1 |
| Baker, J | 1 |
| Chen, Y | 1 |
| Chao, NJ | 1 |
| Rovelli, A | 1 |
| Arrigo, C | 1 |
| Nesi, F | 1 |
| Balduzzi, A | 1 |
| Nicolini, B | 1 |
| Locasciulli, A | 1 |
| Vassallo, E | 1 |
| Miniero, R | 1 |
| Uderzo, C | 1 |
| Hussein, MA | 1 |
| Folkman, J | 1 |
| Kirn, TF | 1 |
| Shiono, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance[NCT00572169] | Phase 3 | 177 participants (Actual) | Interventional | 2006-11-30 | Active, not recruiting | ||
| A Phase 2 Study Incorporating Bone Marrow Microenvironment (ME) Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DT PACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance[NCT00081939] | Phase 2 | 303 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
In patients with no confirmed Partial Response, Near Complete Response, or Complete Response, progression was defined as a >25% increase from baseline in myeloma protein production or other signs of disease progression such as hypercalcemia, etc. (NCT00081939)
Timeframe: 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Study Treatment | 77 |
7 reviews available for thalidomide and Leukemia
| Article | Year |
|---|---|
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antib | 2008 |
[Molecular-targeted drugs. 1) Indications and the application of molecular-targeted drugs in hematological diseases].
Topics: Antigens, CD; Antigens, CD20; Antigens, Differentiation, Myelomonocytic; Autoantibodies; Humans; Leu | 2009 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical | 2011 |
The evolving role of lenalidomide in the treatment of hematologic malignancies.
Topics: Amyloidosis; Antineoplastic Agents; Hematologic Neoplasms; Humans; Lenalidomide; Leukemia; Myelodysp | 2007 |
Research on thalidomide in solid tumors, hematologic malignancies, and supportive care.
Topics: Antioxidants; DNA Damage; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Neoplasms; Neovascul | 2000 |
Angiogenesis-dependent diseases.
Topics: Angiogenesis Inhibitors; Animals; Humans; Leukemia; Multiple Myeloma; Neovascularization, Pathologic | 2001 |
[Diseases and dermatoglyphics].
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Bone and Bones; Chromosome Aberrations; Chromo | 1970 |
3 trials available for thalidomide and Leukemia
| Article | Year |
|---|---|
[The short-term outcomes of patients with acute leukemia treated by thalidomide].
Topics: Acute Disease; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Bone Marrow; Child; Female; Humans; | 2003 |
Thalidomide as salvage therapy for chronic graft-versus-host disease.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Constipation; Cyclosporine; | 1995 |
The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
Topics: Adolescent; Adult; Anemia; Bone Marrow Transplantation; Child; Child, Preschool; Female; Graft vs Ho | 1998 |
18 other studies available for thalidomide and Leukemia
| Article | Year |
|---|---|
Cell differentiation inducers derived from thalidomide.
Topics: Antineoplastic Agents; Cell Differentiation; Drug Screening Assays, Antitumor; Flow Cytometry; HL-60 | 2005 |
Discovering a new analogue of thalidomide which may be used as a potent modulator of TNF-alpha production.
Topics: Cell Line, Tumor; Cell Proliferation; Humans; Leukemia; Thalidomide; Tumor Necrosis Factor-alpha | 2009 |
Response adaptive salvage with KTd and ASCT for functional high-risk multiple myeloma-The Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2023 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid | 2013 |
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acid | 2013 |
Lenalidomide in adult T-cell leukaemia-lymphoma.
Topics: Adult; Antineoplastic Agents; Humans; Lenalidomide; Leukemia; Leukemia-Lymphoma, Adult T-Cell; T-Lym | 2016 |
Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
Topics: Animals; Antigens, CD34; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Humans; Leukemi | 2017 |
Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Death; Cell Line, Tumor; DNA-Binding Prot | 2008 |
Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzym | 2008 |
Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1.
Topics: Cell Movement; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; HL-60 Cells; | 2009 |
Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways.
Topics: B-Lymphocytes; Blotting, Western; Cell Adhesion; Cell Movement; Cells, Cultured; Gelatinases; Humans | 2010 |
Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Diterpenes; Enzyme Inhibitors; Epoxy Compounds | 2011 |
Advances in paediatrics.
Topics: Child; Drug Therapy; Humans; Leukemia; Nephrotic Syndrome; Pediatrics; Phenylketonurias; Thalidomide | 1962 |
STUDIES ON THE POSSIBLE ANTI-NEOPLASTIC EFFECT OF THALIDOMIDE.
Topics: Adenocarcinoma; Antineoplastic Agents; Leukemia; Leukemia, Experimental; Mice; Neoplasms; Neoplasms, | 1963 |
EFFECT OF THALIDOMIDE ON TRANSPLANTABLE MOUSE, RAT, AND HAMSTER TUMORS.
Topics: Animals; Cricetinae; Infections; Injections; Injections, Intraperitoneal; Leukemia; Leukemia, Experi | 1964 |
[STUDIES IN REGARD TO THE POSSIBLE ANTI-NEOPLASTIC EFFECT OF THALIDOMIDE].
Topics: Antineoplastic Agents; Leukemia; Leukemia, Experimental; Mice; Neoplasms; Neoplasms, Experimental; P | 1963 |
Selective leukemic-cell killing by a novel functional class of thalidomide analogs.
Topics: Calcium Signaling; Cell Death; Cell Line, Transformed; Drug Evaluation, Preclinical; Endoplasmic Ret | 2006 |
Does thalidomide affect IL-2 response and production?
Topics: beta-Galactosidase; Cells, Cultured; Clone Cells; Dose-Response Relationship, Drug; Enhancer Element | 1995 |
Quest to improve marrow transplant success yields new approaches to graft-vs-host disease.
Topics: Bone Marrow Transplantation; Graft vs Host Disease; Humans; Leukemia; Thalidomide | 1987 |